Gerber Kawasaki Wealth & Investment Management Raises Stake in Stryker Co. (NYSE:SYK)

Gerber Kawasaki Wealth & Investment Management raised its position in Stryker Co. (NYSE:SYK - Free Report) by 158.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,092 shares of the medical technology company's stock after purchasing an additional 2,511 shares during the quarter. Gerber Kawasaki Wealth & Investment Management's holdings in Stryker were worth $1,474,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rinkey Investments increased its position in shares of Stryker by 1.1% during the fourth quarter. Rinkey Investments now owns 2,712 shares of the medical technology company's stock worth $976,000 after acquiring an additional 30 shares during the period. Bolthouse Investments LLC purchased a new position in Stryker during the fourth quarter valued at approximately $278,000. Virtus ETF Advisers LLC increased its holdings in Stryker by 20.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,228 shares of the medical technology company's stock valued at $1,162,000 after buying an additional 559 shares during the period. Coldstream Capital Management Inc. increased its holdings in Stryker by 3.7% during the fourth quarter. Coldstream Capital Management Inc. now owns 7,621 shares of the medical technology company's stock valued at $2,744,000 after buying an additional 273 shares during the period. Finally, New Vernon Investment Management LLC boosted its stake in Stryker by 793.5% in the fourth quarter. New Vernon Investment Management LLC now owns 19,300 shares of the medical technology company's stock valued at $6,949,000 after acquiring an additional 17,140 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.8 %

NYSE:SYK traded up $3.14 during mid-day trading on Wednesday, hitting $374.06. The stock had a trading volume of 2,251,733 shares, compared to its average volume of 1,353,911. The stock has a 50-day simple moving average of $367.06 and a two-hundred day simple moving average of $373.49. The company has a market capitalization of $142.77 billion, a PE ratio of 48.20, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.90%. Stryker's dividend payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Stifel Nicolaus lifted their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Canaccord Genuity Group raised their target price on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Finally, Wells Fargo & Company raised their target price on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus target price of $423.53.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.